A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients
Phase of Trial: Phase II
Latest Information Update: 05 Jul 2017
At a glance
- Drugs Oxymetazoline (Primary)
- Indications Faecal incontinence
- Focus Therapeutic Use
- Sponsors RDD Pharma
- 05 Jul 2017 According to an RDD Pharma media release, the European Medicines Agency's Committee has granted orphan designation for RDD-0315, an investigational drug for the treatment of fecal incontinence in patients with spinal cord injury.
- 24 May 2016 Primary endpoint (The number of fecal incontinence episodes in 12 hours post drug administration) has been met according to the results presented at the Digestive Disease Week 2016.
- 24 May 2016 Results assessing the effect of oxymetazoline on fecal incontinence presented at the Digestive Disease Week 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History